2016 Fiscal Year Final Research Report
Investigation of a therapy for prostate cancer by inhibition of GGCT expression
Project/Area Number |
15K20084
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Urology
|
Research Institution | Shiga University of Medical Science |
Principal Investigator |
Hanada Eiki 滋賀医科大学, 医学部, 助教 (40555067)
|
Project Period (FY) |
2015-04-01 – 2017-03-31
|
Keywords | γグルタミルシクロトランスフェラーゼ / RNA干渉 / 前立腺癌 |
Outline of Final Research Achievements |
We studied a therapy for prostate cancer by inhibition of GGCT expression. In the immunohisotochemical study using tissue microarray, GGCT was highly expressed in two sections out of 9 sections (22%) of normal human prostate tissue. On the other hand, GGCT was highly expressed in 35 sections out of 40 sections (78%) of prostate cancer tissue. A significant antiproliferative effect via GGCT-targeting siRNA was shown in prostate cancer cell lines, and combination treatment consisting of Docetaxel and GGCT-targeting siRNA reduced cell viability more than the treatment with Docetaxel alone. Therefore, a therapy for prostate cancer by inhibition of GGCT expression may be an effective method.
|
Free Research Field |
泌尿器癌
|